Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genomics02:02

Genomics

38.4K
Genomics is the science of genomes: it is the study of all the genetic material of an organism. In humans, the genome consists of information carried in 23 pairs of chromosomes in the nucleus, as well as mitochondrial DNA. In genomics, both coding and non-coding DNA is sequenced and analyzed. Genomics allows a better understanding of all living things, their evolution, and their diversity. It has a myriad of uses: for example, to build phylogenetic trees, to improve productivity and...
38.4K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

2.2K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone.

Future oncology (London, England)·2026
Same authorSame journal

Nuanced treatment decision in newly diagnosed multiple myeloma patients aged 65-75 years: a real-world study.

Blood research·2026
Same author

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

The New England journal of medicine·2026
Same author

Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01).

Blood·2026
Same author

Clonal Hematopoiesis of Indeterminate Potential and Kidney Failure in Chronic Kidney Disease: An East Asian Cohort Study.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry.

Blood cancer journal·2026

Related Experiment Video

Updated: Nov 7, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.3K

Genomics of diffuse large B cell lymphoma.

Youngil Koh1

  • 1Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.

Blood Research
|May 3, 2021
PubMed
Summary

Next-generation sequencing (NGS) reveals diffuse large B-cell lymphoma (DLBCL) heterogeneity through mutations, shifting classification from cell of origin to mutation-based. This approach is key for future precision treatments in DLBCL.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) classification traditionally relied on cell of origin.
  • Next-generation sequencing (NGS) has uncovered significant molecular heterogeneity within DLBCL.
  • Understanding these molecular drivers is crucial for improving treatment strategies.

Purpose of the Study:

  • To re-evaluate the classification of DLBCL based on mutation profiles.
  • To identify key genetic drivers of DLBCL using advanced sequencing technologies.
  • To explore the relationship between DLBCL subtypes and other non-Hodgkin lymphomas.

Main Methods:

  • Utilized next-generation sequencing (NGS) for comprehensive DNA mutation analysis.
  • Integrated RNA expression data with DNA mutation results.
Keywords:
ClassificationClusteringDLBCLGenomicsNGSRNA

More Related Videos

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.0K
Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
13:21

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

10.3K

Related Experiment Videos

Last Updated: Nov 7, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.3K
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.0K
Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
13:21

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

10.3K
  • Analyzed mutation patterns including B-cell receptor pathway, EZH2, and NOTCH mutations.

    • Main Results:

    • NGS identified distinct mutation profiles driving DLBCL.
    • Mutation-based classification is emerging as a replacement for cell of origin-based methods.
    • B-cell receptor pathway activation, EZH2, and NOTCH mutations are identified as key DLBCL drivers.
    • DLBCL subtypes show similarities to other non-Hodgkin lymphomas based on integrated data.

    Conclusions:

    • NGS-based mutation analysis is fundamentally changing DLBCL classification.
    • Specific mutations are confirmed as critical drivers of DLBCL pathogenesis.
    • Integrated genomic and transcriptomic data provide insights into DLBCL subtypes and their relation to other lymphomas.
    • Precision treatment strategies for DLBCL will increasingly rely on NGS-based molecular dissection.